23532890 |
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET
Pennacchietti, S,
Serini, G,
Valdembri, D,
Michieli, P,
Vigna, E,
Arena, S,
Chiriaco, C,
Basilico, C,
Bardelli, A
|
Clin Cancer Res |
2013 |
19260711 |
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily
Schmidt, RJ,
Henley, B,
Kamath, A,
Lippy, J,
Schroeder, GM,
Jeyaseelan, R,
Zhang, Y,
Tokarski, JS,
Kim, K,
Zhang, Y,
Wei, D,
Clark, C,
Dai, J,
An, Y,
Trainor, GL,
Wautlet, BS,
Chen, XT,
Sack, JS,
Fargnoli, J,
Stefanski, K,
Oppenheimer, S,
Shen, G,
Gullo-Brown, J,
Manne, V,
Lombardo, LJ,
Cornelius, LA,
Hunt, JT,
Borzilleri, RM,
Gupta, A,
Cai, ZW,
Williams, DK
|
J Med Chem |
2009 |
14500382 |
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase
Liang, C,
Quinnan, LA,
Salgia, R,
Ma, P,
Shirazian, S,
Podar, K,
Chu, SC,
Pride, YB,
Gramlich, JL,
Sattler, M,
Christensen, JG
|
Cancer Res |
2003 |
33731699 |
OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer
Meyer, E,
Steenbrugge, J,
Perera, T,
Demeyere, K,
Vander Elst, N,
Van Den Broeck, W,
Sanders, NN,
De Wever, O,
Ciamporcero, E
|
NPJ Breast Cancer |
2021 |
20484018 |
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity
Leggett, DS,
Munshi, N,
France, DS,
Hill, J,
Moussa, MM,
Li, CJ,
Li, Y,
Jeay, S,
Chen, CR,
Ashwell, MA
|
Mol Cancer Ther |
2010 |
20145145 |
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor
Kohl, NE,
Kunii, K,
Davis, LJ,
Hatch, H,
Zeng, Q,
Lu, W,
Paweletz, CP,
Gibbs, JB,
Chan, GK,
Kariv, I,
Jewell, JP,
Gil, S,
Szewczak, AA,
Reilly, JF,
Qu, X,
Katz, JD,
Chi, A,
Deshmukh, SV,
Chenard, M,
Lutterbach, BA,
Dinsmore, CJ,
Hang, G,
Pan, BS
|
Cancer Res |
2010 |
29674709 |
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Comoglio, PM,
Boccaccio, C,
Trusolino, L
|
Nat Rev Cancer |
2018 |
21655918 |
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
Fujiwara, Y,
Mukohara, T,
Kataoka, Y,
Tomioka, H,
Minami, H,
Hirakawa, K,
Yashiro, M,
Kiyota, N,
Funakoshi, Y,
Hirai, M
|
Invest New Drugs |
2012 |
28131876 |
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
Zhang, YK,
Yu, XY,
Zhu, XJ,
Barbuti, AM,
Zhang, GN,
Chen, ZS,
Wen, AW,
Wang, YJ,
Wurpel, JND
|
Pharmacol Res |
2017 |
24700742 |
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET
Wang, J,
Shang, C,
Chen, W,
Xiang, Q,
Chen, Y,
Ren, M,
Deng, DY,
Zhang, L,
Zhang, H
|
Clin Cancer Res |
2014 |
25148209 |
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer
Cui, Y,
Wang, J,
Fan, S,
Wang, Q,
Gu, Y,
Zhang, Z,
Weng, J,
Zhou, F,
Qing, W,
Jia, H,
Dai, G,
Zhou, J,
Jiao, L,
Su, W,
Sai, Y,
Ren, Y
|
J Med Chem |
2014 |
21926191 |
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
Shi, Y,
Orf, J,
Yamaguchi, K,
Engst, S,
Chou, YC,
Chen, J,
Yu, P,
Tan, J,
Laird, AD,
Bentzien, F,
Joly, AH,
Yakes, FM,
Lee, L,
You, A,
Cancilla, B,
Lesch, J,
Chu, F,
Qian, F
|
Mol Cancer Ther |
2011 |
19808973 |
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases
Greshock, J,
Tam, D,
Zaks, T,
Mock, L,
Yamaguchi, K,
Engst, S,
Tan, J,
Yu, P,
Bentzien, F,
Joly, AH,
Wooster, R,
Lougheed, J,
Xu, W,
Yakes, FM,
Li, C,
Qian, F,
Lou, T,
Won, KA
|
Cancer Res |
2009 |
25248999 |
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models
Lv, J,
Gavine, PR,
Fan, S,
Wang, L,
Han, L,
Su, X,
Xu, W,
Wang, QM,
Wang, H,
Liu, YJ,
Zhang, W,
Zhou, F,
Qing, W,
Fu, H,
Jiao, L,
Yin, X,
Su, W,
Xie, L,
Zhang, T,
Xu, S,
Yu, Y,
Ren, Y
|
Mol Oncol |
2015 |
30934578 |
Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents
Zhou, Y,
Yan, M,
Li, XS,
Zhang, NN,
An, BJ
|
Molecules |
2019 |
14612533 |
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo
Chen, J,
Ruslim, L,
Cui, JJ,
Cherrington, JM,
Blake, R,
Kuruganti, P,
Ramphal, J,
Do, S,
Lipson, KE,
Wang, X,
Burrows, J,
Chan, E,
Le, P,
Schreck, R,
Christensen, JG,
Mendel, DB
|
Cancer Res |
2003 |
19832844 |
E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
Asada, M,
Yamaguchi, A,
Obaishi, H,
Funasaka, S,
Matsushima, T,
Nakagawa, T,
Takahashi, K,
Tohyama, O,
Shirotori, S
|
Cancer Sci |
2010 |
17325667 |
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
Swart, R,
Bearss, D,
Simons, B,
Cooke, L,
Wisner, L,
Della Croce, K,
Riley, C,
Garewal, H,
Mahadevan, D,
Iorio, M,
Nagle, R,
Shakalya, K
|
Oncogene |
2007 |
27196782 |
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Dussault, I,
Werner, J,
Moriguchi, J,
Zhang, Y,
Hughes, PE,
Choquette, DM,
Coxon, A,
Radinsky, R,
Kaplan-Lefko, PJ,
Kendall, R,
Caenepeel, S,
Burgess, TL,
Broome, MA,
Damore, MA,
Amore, B,
Yang, Y,
Harmange, JC,
Rex, K,
Baker, D,
Kha, HT
|
Mol Cancer Ther |
2016 |
21918175 |
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3
Hall, LM,
Liu, X,
Yao, W,
Scherle, PA,
Newton, RC,
Yang, G,
Xu, M,
Wang, Q,
Wynn, R,
He, C,
Diamond, S,
Boer, J,
Behshad, E,
Li, Y,
Koblish, HK,
Zhuo, J,
Fridman, JS,
Marando, C
|
Clin Cancer Res |
2011 |
24233399 |
Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells
Zhang, R,
Yao, HP,
Hu, X,
Zhou, YQ,
Wang, MH,
Sharma, S,
Zeng, JY
|
Mol Cancer Ther |
2014 |
24326130 |
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
Shentu, S,
Phillip, CJ,
Zaman, S,
Stellrecht, CM,
Baladandayuthapani, V,
Wang, M,
Taverna, P,
Gandhi, V,
Zhang, J,
Redkar, S,
Balakrishnan, K
|
J Hematol Oncol |
2013 |
19934279 |
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Do, TH,
Leon, BC,
Smyth, L,
Holme, K,
Peterman, MC,
Reich, SH,
Thompson, DA,
Emtage, S,
Aubol, BE,
Buchanan, SG,
Hendle, J,
Schwinn, KD,
Russell, M,
Sauder, JM,
Gessert, SF,
Smith, CR,
Adams, J,
Burley, SK,
Pelletier, LA,
Jessen, KA,
Rooney, IA,
Bounaud, PY,
Blaney, JM,
Huser, NH,
Sprengeler, PA,
Froning, KJ,
Wasserman, SR,
Lee, PS,
Atwell, S,
Tang, CM,
Felce, JD
|
Mol Cancer Ther |
2009 |
|
Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models
Lu, T,
Wroblowski, B,
Libouban, M,
Jovcheva, E,
Ogata, S,
Mevellec, L,
Perera, T,
Clack, G,
Janssens, B,
De Lange, D,
Verhulst, T
|
|
|
17483355 |
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Alton, G,
Nambu, MD,
Arango, ME,
Koudriakova, TB,
Zou, HY,
Los, G,
Bender, SL,
Li, Q,
Cui, JJ,
Mroczkowski, B,
Lee, JH,
McDonnell, SR,
Yamazaki, S,
Christensen, JG,
Kung, PP
|
Cancer Res |
2007 |
31940916 |
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Wu, ZX,
Wang, JQ,
Teng, QX,
Lusvarghi, S,
Yang, Y,
Chen, ZS,
Ambudkar, SV,
Lei, ZN,
Wang, JQ,
Yang, DH
|
Cancers (Basel) |
2020 |
28765324 |
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Shapiro, GI,
Chudova, DI,
Patel, SP,
Lee, M,
Tassell, V,
Aranda, R,
Lanman, RB,
Chao, R,
Baños, N,
Essenburg, CJ,
Madaj, Z,
Christensen, JG,
Hidalgo, M,
Lopez-Casas, PP,
Peled, N,
Jänne, PA,
Awad, MM,
Menendez, C,
Graveel, C,
Nishino, M,
Olson, P,
Hallin, J,
Briere, D,
Tovar, EA,
Engstrom, LD,
Chiang, H,
Bazhenova, L
|
Clin Cancer Res |
2017 |